1-3 of 3
Sybil Zildjian
Close
Sort by
Journal Articles

Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis.

Asher Chanan-Khan, MD, Jeffrey Wolf, MD, Mecide Gharibo, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD, Debbie Manfredi, Kelvin P. Lee, MD, Kena C Miller, NP, Robin Guild, Sybil Zildjian, MPH, Albert Qin, MD, Ph.D., James O'Leary, MD, Robert Vescio, MD
Journal: Blood
Blood (2009) 114 (22): 2883.
https://doi.org/10.1182/blood.V114.22.2883.2883
Published: 2009
Journal Articles

Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma

Asher Alban Chanan-Khan, MD, Mecide Gharibo, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Kenneth C Anderson, MD, Dawn DePaolo, Kelvin P. Lee, MD, Kena Miller, RN, MSN, FNP, Robin Guild, Sybil Zildjian, Albert Qin
Journal: Blood
Blood (2008) 112 (11): 3689.
https://doi.org/10.1182/blood.V112.11.3689.3689
Published: 2008
Journal Articles

Phase I Study of huN901-DM1 (BB-10901) in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma.

Asher A. Chanan-Khan, MD, Sundar Jagannath, MD, Nikhil C. Munshi, MD, Robert L. Schlossman, MD, Kenneth C. Anderson, MD, Kelvin Lee, MD, Dawn DePaolo, Kena C. Miller, NP, Sybil Zildjian, Robert J. Fram, MD, Qin
Journal: Blood
Blood (2007) 110 (11): 1174.
https://doi.org/10.1182/blood.V110.11.1174.1174
Published: 2007